

## **CURRICULUM VITAE**

Simone Ferrero, MD

### **Personal data**

Date of birth: September 9, 1982  
Place of birth: Savigliano (CN), Italy  
Citizenship: Italian  
Marital Status: Unmarried  
Mailing address: Divisione Universitaria di Ematologia  
Via Genova 3, 10126 Torino, Italy  
Fax: + 39-011-696-3737;  
Phone (work): +39-011-633-4220/6884/4251  
E-mail: simone.ferrero@unito.it

### **Education**

2007

Medical degree (with distinction), University of Torino, Italy

2012

Post-graduate degree in Hematology (with distinction), University of Torino, Italy

2012

German language degree “Goethe-Zertifikat B2”, “Goethe Institut” of Berlin, Germany

2015-today

Interuniversity, II level master classes in “Diagnosis and treatment of lymphomas”, University of Udine, Italy

### **Professional records**

2005-2007

Internship, Division of Hematology, University of Torino, Italy

2008-2012

Post-doctoral fellow, Division of Hematology, University of Torino, Italy

2012-today

Research fellow, Division of Hematology, University of Torino, Italy

10/2012-05/2013

Research fellow by “Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Campus Großhadern” and „Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt“ – Munich, Germany

11/2013-12/2013

Research fellow by Molecular genetics laboratory - "Universitätsklinikum S.-H. Campus Kiel 2. Medizinische Klinik und Poliklinik im Städtischen Krankenhaus" - Kiel, Germany.

### **Clinical activity**

Clinical management of onco-hematological in- and out-patients, comprising bone marrow transplantation. Specifically focused on mature lymphoproliferative disorders, comprising patients enrollment in clinical trials.

### **Didactical activity**

- Supervision of several master degree students in Medicine (5) and Medical Biotechnology (7).
- Frontal lessons, as support of the Medical Biotechnology master classes of the university of Torino ("INT0637A - TERAPIE BIOTECNOLOGICHE IN EMATOLOGIA", INT0637 - TERAPIE BIOTECNOLOGICHE"): 2 hours in 2015 and 2 hours in 2016

### **Editorial activity**

- Associate Editor for *BMC Pharmacology & Toxicology*
- Reviewer for *Critical Reviews in Oncology/Hematology*, *Clinical Lymphoma*, *Myeloma & Leukemia* and *BMC Pharmacology & Toxicology*

### **Memberships**

Italian Lymphoma Foundation (FIL)  
FIL Minimal Residual Disease (MRD) Network  
Italian Society of Experimental Hematology (SIES)  
European Hematology Association (EHA)  
European Mantle Cell Lymphoma (MCL) Network  
Euro Clonality MRD Next-generation sequencing and Euro MRD working group, from European Scientific Foundation of Laboratory Hemato Oncology (ESLHO)  
Castleman Disease Collaborative Network

### **Awards and honors**

2016 - "Daniele Rosa" Prize, for research in lymphoproliferative disorders, Torino, Italy  
2015 - "Ercole Brusamolino" Prize, for lymphoma research, Napoli, Italy (FIL, Italian Lymphoma Foundation)  
2015 - "The best scientific proposal" title, during the "FIL cantera tutorial: Malignant Lymphomas, from bench to bedside"  
2014 - 3rd Prize „Under40 in Hematology“, Roma, Italy (SIE, Italian Society of Hematology)

### **Current grant support**

2015 - „Bando Ricerca e Istruzione“, Fondazione Cassa di Risparmio di Torino, Torino, Italy

## Spoken languages

Italian: mother tongue

English: very good in writing and speaking

German: very good in writing and speaking

## Scientific interests

- Diagnosis, clinics and treatment of lymphoproliferative diseases
- Design and conduction of clinical trials in lymphoproliferative diseases
- Minimal residual disease assessment by PCR and Next Generation Sequencing in non-Hodgkin lymphoma and multiple myeloma
- Molecular pathogenesis of lymphoma and multiple myeloma
- Genetics of immunoglobulin genes and chromosomal translocations
- Biological prognostic factors in non Hodgkin lymphoma and chronic lymphocytic leukemia
- Clinics and research of Castleman disease

## Ongoing projects

Currently actively involved in several national and international working groups, mainly focusing on lymphoma research and application of molecular biotechnologies in clinics.

- The principal ongoing collaborations are the following: FIL subcommittee for biological studies, FIL subcommittee for aggressive lymphomas, FIL subcommittee for indolent lymphomas, Italian FIL MRD Network, European MCL Network, Euro MRD and Euro Clonality Next-generation sequencing working group.
- Moreover, in the past two years Dr. Ferrero participated, as PI or collaborator, in several jointed grant applications with the following collaborators: University of Pavia (IT), University of Piemonte Orientale (IT), University of Torino (both Department of Molecular Biotechnologies and Health Sciences and Department of Computer Sciences, IT), Politecnico of Torino (IT), University of Kiel (DE), University of Salamanca (ES) and The Royal Marsden Cancer Diagnostic Centre, Sutton (UK).

## Scientific Production

Official H-index: 11

## Manuscripts

1. Mondello P, Steiner N, Willenbacher W, Wasle I, Zaja F, Zambello R, Visentin A, Endri M, **Ferrero S**, Ghione P, Pitini V, Cuzzocrea S and Mian M. Bendamustine plus Rituximab versus R-CHOP as first-line treatment for patient with Indolent Non-Hodgkin's Lymphoma: evidence from a multicenter, retrospective study. *Annals of Hematology* 2016. *In press*

2. Mondello P, Steiner N, Willenbacher W, **Ferrero S**, Ghione P, Marabese A, Pitini V, Cuzzocrea S and Mian M. Lenalidomide in Relapsed or Refractory Diffuse Large B Cell Lymphoma: Is It a Valid Treatment option?. *The Oncologist* 2016. *In press*.
3. Dreyling M, **Ferrero S**; European Mantle Cell Lymphoma Network. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?. *Haematologica*. 2016 Feb;101(2):104-14. doi: 10.3324/haematol.2014.119115
4. Ladetto M, **Ferrero S**, Drandi D, Festuccia M, Patriarca F, Mordini N, Cena S, Benedetto R, Guarona G, Ferrando F, Brunello L, Ghione P, Boccasavia V, Fanin R, Omedè P, Giaccone L, Palumbo A, Passera R, Boccadoro M and Bruno B. Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma. *Leukemia*. 2015 Oct 6. doi: 10.1038/leu.2015.269
5. **Ferrero S**, Pastore A, Scholz CW, Forstpointner R, Pezzutto A, Bergmann L, Truemper L, Finke J, Keller U, Ghione G, Passera R, Hiddemann W, Weigert O, Unterhalt M, Dreyling M. Radioimmunotherapy In Relapsed/Refractory Mantle Cell Lymphoma Patients: Final Results Of a European MCL Network Phase II Trial. *Leukemia*. 2015 Aug 5. doi: 10.1038/leu.2015.215.
6. Riera L, Osella-Abate S, Benevolo G, Beggiato E, **Ferrero S**, Pich A, and Francia di Celle P. Novel CALR somatic mutations in essential thrombocytemia. *British Journal of Hematology* 2015 Sep 7. doi: 10.1111/bjh.13638.
7. Drandi D, Kubiczko-Besse L, **Ferrero S**, Dani N, Passera R, Mantoan B, Gambella M, Monitillo L, Saraci E, Ghione P, Genuardi E, Barbero D, Omedè P, Barberio D, Hajek R, Vitolo U, Palumbo A, Cortelazzo S, Boccadoro M, Inghirami G and Ladetto M. Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma and follicular lymphoma: a comparison with real-time PCR. *J Mol Diagn*. 2015 Aug 26. pii: S1525-1578(15)00147-6. doi: 10.1016/j.jmoldx.2015.05.007.
8. Dreyling M, **Ferrero S**; European Mantle Cell Lymphoma Network. Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience. *Haematologica*. 2015 Jun;100(6):706-8. doi: 10.3324/haematol.2015.127472.
9. Tedeschi A, Picardi P, **Ferrero S**, Benevolo G, Casaluci Margiotta G, Varettoni M, Baratè C, Motta M, Gini G, Goldaniga MC, Visco C, Zaja F, Belsito Petrizi V, Ravelli E, Gentile M, Urbano MA, Franceschetti S, Ghione P, Orsucci L, Frustaci AM, Gaidano G, Vitolo U, Morra E. (2015). Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström's macroglobulinemia. *LEUKEMIA & LYMPHOMA*, ISSN: 1042-8194
10. Dreyling M, **Ferrero S**, Vogt N, Klapper W, on behalf of European Mantle Cell Lymphoma Network. New paradigms in Mantle Cell Lymphoma: is it time to risk stratify treatment based on the proliferative signature? *Clinical Cancer Research*. 2014 Clin Cancer Res. 2014 Oct 15;20(20):5194-206. doi: 10.1158/1078-0432.CCR-14-0836.
11. Dreyling M, **Ferrero S**; European Mantle Cell Lymphoma Network. How to treat old MCL patients: one size fits it all? *Blood*. 2014 Aug 21;124(8):1207-8. doi: 10.1182/blood-2014-06-578872.
12. **Ferrero S**, Ladetto M, Drandi D, Cavallo F, Genuardi E, Urbano M, Caltagirone S, Grasso M, Rossini F, Guglielmelli T, Cangialosi C, Liberati AM, Callea V, Carovita T, Crippa C, De Rosa L, Pisani F, Pia Falcone A, Pregno P, Oliva S, Terragna C, Musto P, Passera R, Boccadoro M, Palumbo A. Long-term results of the gimema vel-03-096 trial in mm patients receiving vtd consolidation after asct: mrd kinetics impact on survival. *LEUKEMIA*. 2014 Jul 16. doi: 10.1038/leu.2014.219.
13. Dreyling M, **Ferrero S**, Hermine O. How I manage mantle cell lymphoma. *LEUKEMIA*. 2014 May 23. doi: 10.1038/leu.2014.171. [Epub ahead of print]
14. Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Schatz J, Teruya-Feldstein J, Hochberg E, Louissaint A, Dorfman D, Stevenson K, Rodig SJ, Piccaluga PP, Jacobsen E, Pileri SA, Harris NL, **Ferrero S**, Inghirami G, Horwitz SM, Weinstock DM. (2013). A Targeted Mutational Landscape of Angioimmunoblastic T cell Lymphoma. *BLOOD*. 2014 Feb 27;123(9):1293-6. doi: 10.1182/blood-2013-10-531509.
15. Ladetto M, Brüggemann M, Monitillo L, **Ferrero S**, Pepin F, Drandi D, Barbero D, Palumbo A, Passera R, Boccadoro M, Ritgen M, Gökbüget N, Zheng J, Carlton V, Trautmann H, Faham M, Pott C. (2013)

Next-generation sequencing and Real-Time Quantitative PCR for minimal residual disease (MRD) detection using the immunoglobulin heavy chain variable region: a methodical comparison in acute lymphoblastic leukemia (ALL), mantle cell lymphoma (MCL) and multiple myeloma (MM). *LEUKEMIA*. 2013 Dec 17. doi: 10.1038/leu.2013.375

16. **Ferrero S**, Monitillo L, Mantoan B, Barbero D, Genuardi E, Bernocco E, Caracciolo D, Ruella M, Drandi D, Zanni M, Gueli A, Renna F, Lobetti Bodoni C, Barbiero S, Musto P, Boccadoro M, Tarella C, Ladetto M (2013). Pre-emptive rituximab-based treatment of molecular relapses in follicular and mantle cell lymphoma. *ANNALS OF HEMATOLOGY*. Nov;92(11):1503-11. doi: 10.1007/s00277-013-1797-y
17. **Ferrero S**, Dreyling M (2013). The current therapeutic scenario for relapsed mantle cell lymphoma. *CURRENT OPINION IN ONCOLOGY*. Sep;25(5):452-62.
18. Pregno P, Chiappella A, Bellò M, Botto B, **Ferrero S**, Franceschetti S, Giunta F, Ladetto M, Limerutti G, Menga M, Nicolosi M, Priolo G, Puccini B, Rigacci L, Salvi F, Vaggelli L, Passera R, Bisi G, Vitolo U. (2012). The interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. *BLOOD*, vol. Jan 10., ISSN: 0006-4971
19. **Ferrero S**, Capello D, Svaldi M, Boi M, Gatti D, Drandi D, Rossi D, Barbiero S, Mantoan B, Mantella E, Zanni M, Ghione P, Larocca A, Passera R, Bertoni F, Gattei V, Forconi F, Laurenti L, Del Poeta G, Marasca R, Cortelazzo S, Gaidano G, Palumbo A, Boccadoro M, Ladetto M. (2011). Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. *HAEMATOLOGICA*, vol. Dec 29., ISSN: 0390-6078
20. Lamorte S, **Ferrero S**, Aschero S, Monitillo L, Bussolati B, Omedè P, Ladetto M, Camussi G. (2011). Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cell.. *LEUKEMIA*, vol. Oct 25, ISSN: 0887-6924, doi: 10.1038/leu.2011.290
21. **FERRERO S**, DRANDI D, MANTOAN B, GHIONE P, OMEDE P AND LADETTO M (2011). Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms. *HEMATOLOGICAL ONCOLOGY*, vol. 29, p. 167-176, ISSN: 0278-0232, doi: 10.1002/hon.989
22. LADETTO M, **FERRERO S**, BARBIERO S (2011). La terapia del linfoma mantellare: un esempio di integrazione tra biologia e clinica. *SEMINARI DI EMATOLOGIA ONCOLOGICA*, vol. 8
23. LADETTO M, PAGLIANO G, **FERRERO S**, CAVALLO F, DRANDI D, SANTO L, CRIPPA C, DE ROSA L, PREGNO P, GRASSO M, LIBERATI AM, CARAVITA T, PISANI F, GUGLIELMELLI T, CALLEA V, MUSTO P, CANGIALOSI C, PASSERA R, BOCCADORO M, PALUMBO A (2010). Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. *JOURNAL OF CLINICAL ONCOLOGY*, vol. 28(12), p. 2077-2084, ISSN: 0732-183X
24. ROSSI D, LOBETTI BODONI C, GENUARDI E, MONITILLO L, DRANDI D, CERRI M, DEAMBROGI C, RICCA I, ROCCI A, **FERRERO S**, BERNOCCHIO E, CAPELLO D, DE PAOLI L, BERGUI L, BOI M, OMEDE P, MASSAIA M, TARELLA C, PASSERA R, BOCCADORO M, GAIDANO G, LADETTO M (2009). Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. *LEUKEMIA*, vol. 23(6), p. 1062-1072, ISSN: 0887-6924

## Abstracts

1. Daniela Drandi, Elisa Genuardi, Paola Ghione, Daniele Grimaldi, Barbara Mantoan, Marina Ruggeri, Daniela Barbero, Luigia Monitillo, Marika Vasta, Eleonora Marzanati, Giulia Verardo, Paola Omedè, Federica Cavallo, Mario Boccadoro, Marco Ladetto, **Simone Ferrero**. Highly Sensitive Droplet Digital PCR for MYD88L265P Mutation Detection and Minimal Residual Disease Monitoring in Waldenström Macroglobulinemia. *Blood* 2015 126:2645; published ahead of print December 4, 2015
2. Alessandra Tedeschi, Paola Picardi, Maria Cecilia Goldaniga, Gloria Margiotta Casaluci, Giulia Benevolo, **Simone Ferrero**, Marzia Varettoni, Claudia Baratè, Guido Gini, Carlo Visco, Marina Motta, Valeria Belsito Petrizzi, Francesco Zaja, Erica Ravelli, Massimo Gentile, Anna Maria Frustaci, Lorella

Orsucci, Enrica Morra, Gianluca Gaidano, Roberto Cairoli. Long Term Toxicity and Follow-up of Waldenstrom's Macroglobulinemia Patients after Salvage Treatment with Fludarabine Cyclophosphamide Rituximab or Bendamustine and Rituximab. *Blood* 2015 126:3958; published ahead of print December 4, 2015

3. Stefano Luminari, Maria Cecilia Goldaniga, Marina Cesaretti, Sara Rattotti, Marco Frigeni, Alessandra Tedeschi, Paola Picardi, **Simone Ferrero**, Federica Cavallo, Giuseppina Cabras, Michele Merli, Emanuele Cencini, Donato Mannina, Gianluca Gaidano, Angela Ferrari, Giuseppina Ricciuti, Rosanna Cancia, Francesca Re, Marcia Torresan Delamain, Inês B Pereira, Athina Lymboussaki, Vittoria Tarantino, Massimo Federico, Luca Arcaini. Pattern of Care in Indolent Non Follicular Lymphoma: A Report from NF10 Project, an International, Prospective, Observational Study Coordinated By the Fondazione Italiana Linfomi. *Blood* 2015 126:2686; published ahead of print December 4, 2015
4. Davide Rossi, **Simone Ferrero**, Alessio Bruscatin, Paola Ghione, Alice Di Rocco, Valeria Spina, Vittorio Stefani, Giovannino Ciccone, Daniela Barbero, Luigia Monitillo, Maria Gomes Da Silva, Armando Santoro, Annalia Molinari, Andres J.M. Ferreri, Sergio Cortelazzo, Marco Ladetto, Gianluca Gaidano. A Molecular Model for the Prediction of Progression Free Survival in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation: Results from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL). *Blood* 2015 126:336; published ahead of print December 4, 2015
5. Riccardo Bomben, **Simone Ferrero**, Michele Dal Bo, Tiziana D'Agaro, Alessandro Re, Andrea Evangelista, Angelo Michele Carella, Alberto Zamò, Umberto Vitolo, Paola Omedè, Chiara Rusconi, Luca Arcaini, Luigi Rigacci, Stefano Luminari, Sergio Cortelazzo, Marco Ladetto, Valter Gattei. Identification of a Novel Gene Expression Signature in Mantle Cell Lymphoma from the Fondazione Italiana Linfomi (FIL)-MCL-0208 Trial: A Focus on the B Cell Receptor Pathway. *Blood* 2015 126:701; published ahead of print December 4, 2015
6. Carola Boccomini, Marco Ladetto, Francesca Dutto, **Simone Ferrero**, Luca Baldini, Chiara Bottelli, Claudia Castellino, Annalisa Chiarenza, Annarita Conconi, Federico De Angelis, Andrea Evangelista, Stefan Hohaus, Francesco Merli, Benedetta Puccini, Chiara Rusconi, Eleonora Russo, Stefano Sacchi, Stefano Volpetti, Giuseppe Rossi, Umberto Vitolo. LONG-TERM Outcome of a Fondazione Italiana Linfomi Study Comparing Short Rituximab Maintenance Vs Observation after Brief First-LINE R-FND Chemoimmunotherapy Followed By Rituximab Consolidation in Elderly Patients with Advanced Follicular Lymphoma (FL). *Blood* 2015 126:3985; published ahead of print December 4, 2015
7. Michaela Kotrova, Henrik Knecht, Jack Bartram, Vojtech Bystry, Giovanni Cazzaniga, Grazia Fazio, **Simone Ferrero**, Elisa Genuardi, Ramon Garcia-Sanz, Andrea Gironi, Jeremy Hancock, Cristina Jimenez, Marco Ladetto, John Moppett, Simona Songia, Dietrich Herrmann, Christiane Pott, Anton W. Langerak, Nikos Darzentas, Jan Trka, Eva Fronkova, Monika Bruggemann. Library Preparation Is the Major Factor Affecting Differences in Results of Immunoglobulin Gene Rearrangements Detection on Two Major Next-Generation Sequencing Platforms. *Blood* 2015 126:1411; published ahead of print December 4, 2015
8. Stefania Oliva, Manuela Gambella, Milena Gilestro, Francesca Gay, Alessandra Larocca, Anna Marina Liberati, Francesca Bonello, Giulia Benevolo, Giovannino Ciccone, Tommaso Caravita, Vittorio Emanuele Muccio, Simona Caltagirone, Stefano Spada, Barbara Gamberi, **Simone Ferrero**, Marina Ruggeri, Giuseppe Rossi, Elona Saraci, Massimo Offidani, Maria Teresa Petrucci, Mario Boccadoro, Pieter Sonneveld, Antonio Palumbo, Paola Omedè. Minimal Residual Disease Detection By Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: A Preliminary Analysis of the EMN02/HO95 MM Study. *Blood* 2015 126:1760; published ahead of print December 4, 2015
9. Visco C, Chiappella A, Franceschetti S, Patti C, **Ferrero S**, Barbero D, Evangelista A, Spina M, Molinari A, Rigacci L, Tani M, Di Rocco A, Pinotti G, Fabbri A, Zambello R, Finotto S, Gotti M, Carella AM, Salvi F, Pileri SA, Ladetto M, Zaja F, Gaidano G, Vitolo U and Rodeghiero F. Rituximab, bendamustine and cytarabine (RBAC500) as induction therapy in elderly patients with mantle cell lymphoma: a phase 2 study from the Fondazione Italiana Linfomi. *Hematol Oncol* 2015; 33: 100–180 (ICML Meeting Abstract 059).
10. Zaja F, **Ferrero S**, Stelitano C, Ferrari A, Ladetto M, Salvi F, et al. Rituximab, lenalidomide, bendamustine second line therapy in mantle cell lymphoma: a phase II study of the Fondazione Italiana Linfomi (FIL). *Hematol Oncol* 2015; 33: 100–180 (ICML Meeting Abstract 014).

11. Cortelazzo S, Martelli M, Ladetto M, **Ferrero S**, Ciccone G, Evangelista A, et al. High dose sequential chemotherapy with rituximab and ASCT as first line therapy in adult MCL patients: clinical and molecular response of the MCL0208 trial, a FIL study. *Haematologica* 2015 Supp. (European Hematology Association Annual Meeting, Abstract S106)
12. Brüggemann M, Knecht H, Bartram J, Bystry V, Cazzaniga G, Fazio G, **Ferrero S**, Froňkova E, Garcia-Sanz R, Grioni A, Hancock J, Jimenez C, Kotrov M, Ladetto M, Moppett J, Songia S, Trka J, Langerak AW, Darzentas N, Herrmann D and Pott C. International multi-laboratory next-generation sequencing for MRD analysis in ALL. A pilot study by the Euroclonality-NGS consortium. *Haematologica* 2015 Supp. (European Hematology Association Annual Meeting, Abstract P164)
13. Bruno B, **Ferrero S**, Drandi D, Festuccia M, Patriarca F, Mordini N, Cena S, Barbero D, Monitillo L, Ferrando F, Brunello L, Fanin R, Ghione P, Omedè P, Giaccone L, Palumbo A, Passera R, Boccadoro M and Ladetto M. Prospective Molecular Monitoring of Minimal Residual Disease after Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma. *Blood* (ASH Annual Meeting Abstracts), Nov 2014 122:44
14. Gambella M, Omedè P, Oliva S, Gilestro M, Muccio VE, Drandi D, **Ferrero S**, Gay F, Patriarca F, Palladino C, Petrucci MT, Pescosta N, Liberati AM, Caravita T, Di Raimondo F, Rocci A, Musto P, Boccadoro M and Palumbo A. In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide. *Blood* (ASH Annual Meeting Abstracts), Nov 2014 122:3394
15. **Ferrero S**, Pastore A, Forstpointner R, Scholz CW, Pezzutto A, Bergmann L, Truemper L, Finke J, Keller U, Ladetto M, Hiddemann W, Weigert O, Unterhalt M, Dreyling M. Radioimmunotherapy In Relapsed/Refractory Mantle Cell Lymphoma Patients: Final Results Of a European MCL Network Phase II Trial. *Blood* (ASH Annual Meeting Abstracts), Nov 2013 122:4384
16. **Ferrero S**, Ladetto M, Drandi D, Cavallo F, Genuardi E, Urbano M, Guarona G, Callea V, Cangialosi C, Caravita T, Crippa C, De Rosa L, Falcone AP, Grasso M, Guglielmelli T, Liberati AM, Pisani F, Pregno P, Rossini F, Oliva S, Rocci A, Passera R, Boccadoro M, Palumbo A. Long-Term Molecular Results Of The Gimema VEL-03-096 Trial: Molecular Remission Achievement and Loss Are Major Outcome Predictors. *Blood* (ASH Annual Meeting Abstracts), Nov 2013 122:2077
17. Drandi D, Kubiczková L, Dani N, **Ferrero S**, Monitillo L, Mantoan B, Genuardi E, Barbero D, Gambella M, Barberio D, Ghione P, Guarona G, Saraci E, Omedè P, Passera R, Hajek R, Cortelazzo S, Palumbo A, Boccadoro M, Inghirami G, Ladetto M. Improved Igh-Based MRD Detection By Using Droplet Digital PCR: a Comparison With Real Time Quantitative PCR In MCL and MM. *Blood* (ASH Annual Meeting Abstracts), Nov 2013 122:4290
18. Ladetto M, Brüggemann M, **Ferrero S**, Pepin F, Drandi D, Monitillo L, Palumbo A, Passera R, Boccadoro M, Carlton V, Trautmann H, Faham M, Pott C (2012). Next-Generation Sequencing and Real-Time Quantitative PCR for Minimal Residual Disease (MRD) Detection Using the Immunoglobulin Heavy Chain Variable Region: A Methodical Comparison in Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) and Multiple Myeloma (MM). In: *Blood* (ASH Annual Meeting Abstracts), Nov 2012; 120: 788.
19. Ladetto M, **Ferrero S**, Drandi D, Omedè P, Patriarca F, Mordini N, Cena S, Barbero D, Monitillo L, Giaccone L, Rocci A, Barbiero S, Festuccia M, Gallamini A, Fanin R, Passera R, Palumbo A, Boccadoro M, Bruno B (2012). High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma. In: *Blood* (ASH Annual Meeting Abstracts), Nov 2012; 120: 4204. .
20. **Ferrero S**, Monitillo L, Mantoan B, Barbero D, Genuardi E, Bruna R, Bernocco E, Caracciolo D, Ruella M, Drandi D, Zanni M, Gueli A, Renna F, Ghione P, Lobetti Bodoni C, Barbiero S, Musto P, Boccadoro M, Tarella C, Ladetto M (2012). PRE-EMPTIVE RITUXIMAB-BASED TREATMENT OF MOLECULAR RELAPSES IN FOLLICULAR AND MANTLE CELL LYMPHOMA. In: *Haematologica* (EHA Meeting abstracts). Amsterdam (Netherlands), 14-17/06/2012
21. Chiappella A, **Ferrero S**, Frairia C, Puccini B, Arcaini L, Baldi I, Benevolo G, Boccomini C, Botto B, Ciochetto C, Gabutti C, Lobetti Bodoni C, Mian M, Orsucci L, Pregno P, Ladetto M, Vitolo U (2012). THE PROGNOSTIC ROLE OF MANTLE CELL INTERNATIONAL PROGNOSTIC INDEX (MIPI) IN PATIENTS TREATED WITH RITUXIMAB AND HIGH DOSE CHEMOTHERAPY PLUS AUTOLOGOUS

STEM CELL TRANSPLANT. In: Haematologica (EHA Meeting abstracts). Amsterdam (Netherlands), 14-17/06/2012

22. Ladetto M, **Ferrero S**, Drandi D, Cavallo F, Monitillo L, Ghione P, Barbiero S, Grasso M, Rossini F, Guglielmelli T, Cangialosi C, Liberati AM, Callea V, Caravita T, De Rosa L, Pisani F, Falcone AP, Pregno P, Rocci A, Passera R, Boccadoro M, Palumbo A (2011). Long-term results of the GIMEMA VTD Consolidation trial in autografted multiple myeloma patients (VEL-03-096): impact of minimal residual disease detection by Real Time Quantitative PCR on late recurrences and overall survival. In: Blood (ASH Annual Meeting Abstracts). San Diego, 10-13/12/2011
23. Barbero D, Drandi D, Lobetti Bodoni C, Bernocco E, Coscia M, Ruggeri M, Boi M, Genuardi E, Monitillo L, Mantoan B, Maffeo C, Barbiero S, **Ferrero S**, Rossi D, Passera R, Gaidano G, Massaia M, Omede P, Boccadoro M, Ladetto M (2011). EXPRESSION OF TELOMERIC PROTEINS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). In: Haematologica (SIES Meeting abstract book). Napoli, Ottobre 2011
24. Pregno P, Chiappella A, Bellò M, Passera R, Botto B, Castellano G, Ciochetto C, **Ferrero S**, Franceschetti S, Giunta F, Ladetto M, Limerutti G, Nicolosi M, Priolo G, Puccini B, Rigacci L, Salvi F, Vaggelli L, Bisi G, Vitolo U (2011). THE OUTCOME OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IS NOT PREDICTED BY INTERIM 18-FDG-POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY (PET): FINAL ANALYSIS ON 88 PATIENTS TREATED WITH FIRST-LINE R-CHOP. In: Haematologica (SIES Meeting abstract book). Napoli, Ottobre 2011
25. **FERRERO S**, CAPELLO D, SVALDI M, DRANDI D, BOI M, BARBIERO S, GATTI D, ROSSI D, GENUARDI E, ANTICO O, GHIONE P, ZANNI M, ROCCI A, BERTONI F, ZUCCA E, GATTEI V, PALUMBO A, CORTELAZZO S, BOCCADORO M, GAIDANO G AND LADETTO M (2010). IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin. In: Blood (ASH Annual Meeting Abstracts). Orlando (FL), 4-7/12/2010. Orlando (FL), 4-7/12/2010
26. **FERRERO S**, CAPELLO D, SVALDI M, BARBIERO S, GATTI D, DRANDI D, MONITILLO L, BUSSANO S, BOI M, LOBETTI BODONI C, BERTONI F, ZUCCA E, GATTEI V, PALUMBO A, BOCCADORO M, CORTELAZZO S, GAIDANO G, LADETTO M (2010). Le catene pesanti delle immunoglobuline (IGH) non mostrano clustering recettoriale nel mieloma multiplo ma possono essere correlate al repertorio di cellule B normali e di altri tumori linfoidi. In: Haematologica (SIES Meeting abstract book). Torino (Italy), 06-08/10/2010. Torino (Italy), 06-08/10/2010
27. CHIAPPELLA A, PUCCINI B, ROSSI M, ARCAINI L, BALDI I, BENEVOLO G, BOCCOMINI C, BOTTO B, CIOCHETTO C, FABBRI A, **FERRERO S**, FRAIRIA C, LADETTO M, NOVERO D, ORSUCCI L, PAULLI M, PREGNO P, PRIOLO G, RIGACCI L, VITOLO U (2010). L'indice prognostico internazionale per i linfomi mantellari (MIPI) e' un buon indice prognostico di sopravvivenza nei pazienti affetti da linfoma mantellare (MCL) trattati con rituximab e chemioterapia. In: Haematologica (SIES Meeting abstract book). Torino (Italy), 06-08/10/2010. Torino (Italy), 06-08/10/2010
28. **FERRERO S**, CAPELLO DANIELA, SVALDI MIRIJA, BOI MICHELA, GATTI DANIELA, DRANDI DANIELA, MONITILLO LUIGIA, BUSSANO SERENA, BARBIERO SARA, LOBETTI BODONI CHIARA, BERTONI FRANCESCO, ZUCCA EMANUELE, GATTEI VALTER, PALUMBO ANTONIO, BOCCADORO MARIO, CORTELAZZO SERGIO, GAIDANO GIANLUCA, LADETTO MARCO (2010). MULTIPLE MYELOMA (MM) IMMUNOGLOBULIN SEQUENCES SHOW NO INTRA-DISEASE CLUSTERING BUT ARE OCCASIONALLY RELATED TO REPERTOIRES FROM NORMAL LYMPHOCYTES AND OTHER B-CELL TUMORS. In: Haematologica (EHA Meeting abstract book). Barcelona (Spain), 10-13/06/2010
29. CHIAPPELLA A, PUCCINI B, **FERRERO S**, ARCAINI L, BALDI I, BENEVOLO G, BOCCOMINI C, BOTTO B, CIOCHETTO C, CORTELAZZO S, FABBRI S, FRAIRIA C, GABUTTI C, LADETTO M, MIAN M, NOVERO D, ORSUCCI L, PREGNO P, PRIOLO G, RIGACCI L, ROSSI M, RUSCONI C AND VITOLO U (2010). Retrospective Analysis of 206 Mantle Cell Lymphoma Patients at Diagnosis: Mantle Cell International Prognostic Index (MIPI) Is a Good Predictor of Death Event In Patients Treated Either with Rituximab-Chemotherapy or Rituximab-High-Dose-Chemotherapy. In: Blood (ASH Annual Meeting Abstracts). Orlando (FL), 4-7/12/2010. Orlando (FL), 4-7/12/2010



30. LOBETTI BODONI C, FERRERO D, GENUARDI E, PASSERA R, BERNOCCO E, SIA D, CRISÀ E, GRIGNANI G, ROCCI A, MONITILLO L, DRANDI D, GIAI V, **FERRERO S**, BOI M, MANTELLA E, ISAIA G, LUNGHI M, ABRUZZESE E, RADAELLI F, PINI M, PREGNO P, CARLO-STELLA C, GAIDANO G, BOCCADORO M AND LADETTO M (2010). Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity. In: Blood (ASH Annual Meeting Abstracts). Orlando (FL), 4-7/12/2010. Orlando (FL), 4-7/12/2010
31. VITOLO U, CHIAPPELLA A, BELLÒ M, PASSERA R, BOTTO B, CASTELLANO G, CIOCHETTO C, **FERRERO S**, FRAIRIA C, FRANCESCHETTI S, GIUNTA F, LADETTO M, MENGA M, NICOLOSI M, PRIOLO G, PUCCINI B, RIGACCI L, SALVI F, VAGGELLI L, PREGNO P AND BISI G (2010). The Outcome of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP (R-CHOP) Is Not Predicted by 18-FDG-Positron Emission Tomography/Computerized Tomography (PET) Performed at Intermediate In-Course Evaluation, but Only by PET Assessed at the End of Therapy. In: Blood (ASH Annual Meeting Abstracts). Orlando (FL), 4-7/12/2010. Orlando (FL), 4-7/12/2010
32. P PREGNO, A. CHIAPPELLA, M. BELLO, **FERRERO S**, R. PASSERA, C. BOCCOMINI, B. BOTTO, G. CASTELLANO, C. FRAIRIA, S. FRANCESCHETTI, R. FREILONE, M. MENGA, F. SALVI, M. LADETTO, U. VITOLO (2009). EARLY EVALUATION OF 18-FDG-POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY (PET) DOES NOT PREDICT THE OUTCOME IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PATIENTS TREATED WITH R-CHOP. In: Haematologica 2009; 94[suppl.2]:166 abs. 0410. Berlin (Germany), 4-7/06/2009
33. C. LOBETTI BODONI, D. FERRERO, E. GENUARDI, D. SIA, M. GENUARDI, V. GIAI, A. ROCCI, L. MONITILLO, D. DRANDI, A. RISSO, **FERRERO S**, G. ISAIA, M. LUNGHI, R. PASSERA, G. GAIDANO, M. BOCCADORO, C. CARLO-STELLA, M. LADETTO (2009). PH-NEGATIVE HEMATOPOIESIS EMERGING AFTER SUCCESSFUL TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA DYSPLAYS SEVERE AND PERSISTENT TELOMERIC LOSS AND IMPAIRED FUNCTIONAL PERFORMANCES. In: Haematologica 2009; 94[suppl.2]:215 abs. 0529. Berlin (Germany), 4-7/06/2009
34. A. PALUMBO, F. CAVALLO, G. PAGLIANO, **FERRERO S**, D. DRANDI, M. BOI, L. SANTO, P. PREGNO, M. GRASSO, A.M. LIBERATI, T. CARAVITA, F. PISANI, T. GUGLIELMELLI, V. CALLEA, A.P. FALCONE, R. PASSERA, M. BOCCADORO, M. LADETTO (2009). POST TRANSPLANT CONSOLIDATION WITH BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE INDUCES A CLINICALLY SIGNIFICANT SHRINKAGE OF RESIDUAL TUMOR BURDEN MEASURED BY REAL TIME PCR. In: Haematologica 2009; 94[suppl.2]:431 abs. 1071. Berlin (Germany), 4-7/06/2009
35. **FERRERO S**, DANIELA CAPELLO, MIRIJA SVALDI, MICHELA BOI, DANIELA DRANDI, DAVIDE ROSSI, GLORIA PAGLIANO, LUIGIA MONITILLO, CHIARA LOBETTI BODONI, ELISA GENUARDI, ROSSANA CRITELLI, SERENA BUSSANO, DANIELA BARBERO, BARBARA MANTOAN, ELISA BERNOCCO, ANTONIO PALUMBO, MARIO BOCCADORO, GIANLUCA GAIDANO, SERGIO CORTELAZZO, AND MARCO LADETTO (2009). Characteristics of the Immunoglobulin Heavy Chain (IgH) Rearrangement in Multiple Myeloma (MM): An Analysis On 308 Cases. In: Blood (ASH Annual Meeting Abstracts). New Orleans (LA), 5-8/12/2009
36. MARCO LADETTO, GLORIA PAGLIANO, **FERRERO S**, FEDERICA CAVALLO, DANIELA DRANDI, MICHELA BOI, LOREDANA SANTO, CLAUDIA CRIPPA, LUCA DE ROSA, PATRIZIA PREGNO, MARIELLA GRASSO, ANNA MARINA LIBERATI, TOMMASO CARAVITA, FRANCESCO PISANI, TOMMASINA GUGLIELMELLI, VINCENZO CALLEA, FAUSTO ROSSINI, PELLEGRINO MUSTO, CLOTILDE CANGIALOSI, ALBERTO ROCCI, ROBERTO PASSERA, MARIO BOCCADORO, AND ANTONIO PALUMBO (2009). Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone. In: Blood (ASH Annual Meeting Abstracts). New Orleans (LA), 5-8/12/2009
37. PATRIZIA PREGNO, ANNALISA CHIAPPELLA, MARILENA BELLÒ, ROBERTO PASSERA, **FERRERO S**, GIULIA BENEVOLO, CAROLA BOCCOMINI, GIANCARLO CASTELLANO, SILVIA FRANCESCHETTI, MASSIMO MENGA, LORELLA ORSUCCI, GIORGIO PRIOLO, BENEDETTA PUCCINI, LUIGI RIGACCI, FLAVIA SALVI, MARCO LADETTO, AND UMBERTO VITOLO (2009). Interim 18-FDG-Positron Emission Tomography/Computed Tomography (PET) Failed to Predict

Different Outcome in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab-CHOP. In: Blood (ASH Annual Meeting Abstracts). New Orleans (LA), 5-8/12/2009

38. ANNALISA CHIAPPELLA, BENEDETTA PUCCINI, MARIANNA ROSSI, **FERRERO S**, LUCA ARCAINI, ERNESTA AUDISIO, ILEANA BALDI, CAROLA BOCCOMINI, BARBARA BOTTO, FABBRI ALBERTO, CHIARA FRAIRIA, ROBERTO FREILONE, MARCO LADETTO, DOMENICO NOVERO, MARCO PAULLI, PATRIZIA PREGNO, GIORGIO PRIOLO, LUIGI RIGACCI, AND UMBERTO VITOLO (2009). Mantle Cell International Prognostic Index (MIPI) Is a Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab (R) Era. In: Blood (ASH Annual Meeting Abstracts). New Orleans (LA), 5-8/12/2009
39. CHIARA LOBETTI BODONI, DARIO FERRERO, ELISA GENUARDI, DANIELA SIA, MARIELLA GENUARDI, VALENTINA GIAI, ALBERTO ROCCI, LUIGIA MONITILLO, DANIELA DRANDI, **FERRERO S**, GIANLUCA ISAIA, ELISA BERNOCCO, MICHELA BOI, MONIA LUNGHI, ELISABETTA ABRUZZESE, MASSIMO PINI, FRANCA RADAELLI, PATRIZIA PREGNO, ROBERTO PASSERA, GIANLUCA GAIDANO, MARIO BOCCADORO, CARMELO CARLO-STELLA, AND MARCO LADETTO (2009). Ph-Negative Hematopoiesis Emerging After Successful Treatment of Chronic Myeloid Leukemia Displays Severe and Persistent Telomeric Loss Which Is Particularly Prominent in Patients with Acquired Cytogenetic Abnormalities. In: Blood (ASH Annual Meeting Abstracts). New Orleans (LA), 5-8/12/2009
40. A. PALUMBO, F. CAVALLO, G. PAGLIANO, **FERRERO S**, L. SANTO, V. MAGAROTTO, P. PREGNO, M. GRASSO, A.M. LIBERATI, T. CARAVITA, F. PISANI, T. GUGLIELMELLI, C. CRIPPA, L. DE ROSA, D. DRANDI, M. BOCCADORO, M. LADETTO (2008). EARLY CONSOLIDATION WITH BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE IN MM PATIENTS IN CR OR VGPR FOLLOWING AUTOLOGOUS TRANSPLANTATION INDUCES MOLECULAR REMISSIONS. In: Haematologica 2008: 93(s1):76 Abs.0190. Copenhagen (Denmark), 12-15/06/2008
41. M. LADETTO, C. LOBETTI BODONI, E. GENUARDI, M. GENUARDI, V. GIAI, A. ROCCI, L. MONITILLO, D. DRANDI, A. RISSO, B. MANTOAN, **FERRERO S**, R. CRITELLI, C. TARELLA, M. BOCCADORO, D. FERRERO (2008). MARKED TELOMERE EROSION OF PH-NEGATIVE MYELOID CELLS AFTER SUCCESSFUL TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA INDICATES SEVERE PROLIFERATIVE STRESS AND POTENTIAL PERMANENT DAMAGE OF HEMATOPOIESIS. In: Haematologica 2008: 93(s1):349 Abs.0882. Copenhagen (Denmark), 12-15/06/2008
42. D. ROSSI, C. LOBETTI BODONI, E. GENUARDI, L. MONITILLO, M. CERRI, C. DEAMBROGI, D. DRANDI, I. RICCA, A. ROCCI, M. BOI, **FERRERO S**, D. CAPELLO, L. DE PAOLI, L. BERGUI, P. OMEDE, M. MASSAIA, M. BOCCADORO, G. GAIDANO, M. LADETTO (2008). SHORT TELOMERE LENGTH IS AN INDEPENDENT PREDICTOR OF SURVIVAL, PROGRESSION, RICHTER'S SYNDROME TRANSFORMATION AND RECURRENT INFECTIONS: AN ANALYSIS ON 421 CLL PATIENTS INCLUDING BLINDED VALIDATION ON 230 CASES. In: Haematologica 2008: 93(s1):162 Abs.0407. Copenhagen (Denmark), 12-15/06/2008
43. MARCO LADETTO, GLORIA PAGLIANO, **FERRERO S**, FEDERICA CAVALLO, DANIELA DRANDI, MICHELA BOI, LOREDANA SANTO, PATRIZIA PREGNO, MARIELLA GRASSO, ANNA MARINA LIBERATI, TOMMASO CARAVITA, FRANCESCO PISANI, CLAUDIA CRIPPA, VINCENZO CALLEA, ANTONIETTA FALCONE, SERGIO MORANDI, MARIO BOCCADORO, AND ANTONIO PALUMBO (2008). Major Shrinking of Residual Tumor Cell Burden and Achievement of Molecular Remissions in Myeloma Patients Undergoing Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone: A Qualitative and Quantitative PCR Study. In: Blood (ASH Annual Meeting Abstracts). San Francisco (CA), December 2008
44. CHIARA LOBETTI BODONI, DARIO FERRERO, ELISA GENUARDI, DANIELA SIA, MARIELLA GENUARDI, VALENTINA GIAI, ALBERTO ROCCI, LUIGIA MONITILLO, DANIELA DRANDI, ALESSANDRA RISSO, **FERRERO S**, BARBARA MANTOAN, ROSSANA CRITELLI, SERENA BUSSANO, MONIA LUNGHI, ROBERTO PASSERA, CORRADO TARELLA, GIANLUCA GAIDANO, MARIO BOCCADORO, CARMELO CARLO-STELLA, AND MARCO LADETTO (2008). Persistent Telomeric Loss and Functional Impairment of Ph-Negative Hematopoiesis after Successful Treatment of Chronic Myelogenous Leukemia. In: Blood (ASH Annual Meeting Abstracts). San Francisco (CA), December 2008

45. DAVIDE ROSSI, CHIARA LOBETTI BODONI, ELISA GENUARDI, LUIGIA MONITILLO, DANIELA DRANDI, CLARA DEAMBROGI, MICHAELA CERRI, IRENE RICCA, ALBERTO ROCCI, **FERRERO S**, ELISA BERNOCCO, DANIELA CAPELLO, LORENZO DE PAOLI, LUCIANA BERGUI, MICHELA BOI, PAOLA OMEDE', MASSIMO MASSAIA, CORRADO TARELLA, ROBERTO PASSERA, MARIO BOCCADORO, GIANLUCA GAIDANO, AND MARCO LADETTO (2008). Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter's Syndrome Transformation in Chronic Lymphocytic Leukemia. In: Blood (ASH Annual Meeting Abstracts). San Francisco (CA), December 2008
46. MARCO LADETTO, GLORIA PAGLIANO, ILARIA AVONTO, LOREDANA SANTO, **FERRERO S**, FEDERICA CAVALLO, MONICA ASTOLFI, PATRIZIA PREGNO, CLAUDIA CRIPPA, ANNA MARINA LIBERATI, VINCENZO CALLEA, LUCA DE ROSA, ANTONIETTA FALCONE, MARIELLA GRASSO, DANIELA DRANDI, MARIO BOCCADORO, AND ANTONIO PALUMBO (2007). Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients. In: Blood (ASH Annual Meeting Abstracts). Atlanta (GA), December 2007

### Book chapters

1. Drandi D, **Ferrero S** and Ladetto M. Droplet digital PCR for Minimal residual disease detection in mature lymphoproliferative disorders. Springer 2016. *In press*
2. **Ferrero S** and Dreyling M. The Challenge of Treating Elderly Patients with Mantle Cell Lymphoma. © Springer-Verlag London 2015 U. Wedding, R.A. Audisio (eds.), Management of Hematological Cancer in Older People, DOI 10.1007/978-1-4471-2837-3\_9. 2013

*In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, and art. 13 of EU Regulation 2016/679 concerning the protection of individuals personal data, I hereby authorize to use and process my personal details contained in this document.*

*Torino, May the 12th, 2022*

*Dr. Simone Ferrero*